19 October 2025
Johnson & Johnson's Subcutaneous Amivantamab Shows 45% Response Rate in Head and Neck Cancer
Subcutaneous amivantamab offers rapid, durable responses in head and neck cancer, with 82% tumor shrinkage and a median response duration of 7.2 months.